13:55
2026-07-20
cryptobriefing.com
artificial-intelligence
Tempus AI strikes $1.5B deal for Personalis, betting big on AI-powered cancer detection
Tempus AI has agreed to acquire Personalis, Inc. for $1.5 billion, or $16.25 per share, gaining its NeXT Personal minimal residual disease blood test for cancer detection. The deal targets a $20 billi…